检索结果-南通市图书馆

Evaluation of high-resolution satellite precipitation products with surface rain gauge observations from Laohahe Basin in northern China

引用

Water Science and Engineering 2010年第4期3卷 405-417页

作者： shan-hu jiang li-liang ren bin yong xiao-li yang lin shi State Key Laboratory of Hydrology-Water Resources and Hydraulic Engineering Hohai University Nanjing 210098 P. R. China

Three high-resolution satellite precipitation products, the Tropical Rainfall Measuring Mission （TRMM） standard precipitation products 3B42V6 and 3B42RT and the Climate Precipitation Center＇s （CPC） morphing technique precipitation product （CMORPH）, were evaluated against surface rain gauge observations from the Laohahe Basin in northern China. Widely used statistical validation indices and categorical statistics were adopted. The evaluations were performed at multiple time scales, ranging from daily to yearly, for the years from 2003 to 2008. The results show that all three satellite precipitation products perform very well in detecting the occurrence of precipitation events, but there are some different biases in the amount of precipitation. 3B42V6, which has a bias of 21%, fits best with the surface rain gauge observations at both daily and monthly scales, while the biases of 3B42RT and CMORPH, with values of 81% and 67%, respectively, are much higher than a normal receivable threshold. The quality of the satellite precipitation products also shows monthly and yearly variation： 3B42RT has a large positive bias in the cold season from September to April, while CMORPH has a large positive bias in the warm season from May to August, and they all attained their best values in 2006 （with 10%, 50%, and -5% biases for 3B42V6, 3B42RT, and CMORPH, respectively）. Our evaluation shows that, for the Laohahe Basin, 3B42V6 has the best correspondence with the surface observations, and CMORPH performs much better than 3B42RT. The large errors of 3B42RT and CMORPH remind us of the need for new improvements to satellite precipitation retrieval algorithms or feasible bias adjusting methods.

关键词： satellite precipitation product TRMM 3B42RT TRMM 3B42V6 CMORPH surface rain gauge observation Laohahe Basin

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Searching for^(76)Ge neutrinoless double beta decay with the CDEX-1B experiment

引用

Chinese Physics C 2024年第10期48卷 11-22页

作者： bing-Tao Zhang Jun-Zheng Wang li-Tao yang Qian Yue Ke-Jun Kang Yuan-Jing li Hai-Peng An C.Greeshma Jian-Ping Chang Yun-huan Chen Jian-Ping Cheng Wen-Han Dai Zhi Deng Chang-Hao Fang Xin-Ping Geng hui Gong Qiu-Ju Guo Xu-Yuan Guo li He Sheng-Ming He Jin-Wei hu Han-Xiong huang Tu-Chen huang Hai-Tao Jia Xi jiang S.Karmakar Hao-bin li Jian-Min li Jin li Qian-Yun li ren-Ming-Jie li Xue-Qian li Yu-Lan li Yi-Fan liang bin liao Fong-Kay lin shin-Ted lin Jia-Xuan liu Shu-Kui liu Yan-Dong liu Yu liu Yuan-Yuan liu Zhong-Zhi liu Hao Ma Yu-Cai Mao Qi-Yuan Nie Jin-hua Ning hui Pan Ning-Chun Qi Jie ren Xi-Chao Ruan Ze She Manoj Kumar Singh Tian-Xi Sun Chang-Jian Tang Wei-You Tang yang Tian Guang-Fu Wang li Wang Qing Wang Yu-Feng Wang Yun-Xiang Wang Henry-Tsz-King Wong shi-yong Wu Yu-Cheng Wu Hao-yang Xing Rui Xu Yin Xu Tao Xue Yu-Lu Yan Nan Yi Chun-Xu Yu Hai-Jun Yu Jian-Feng Yue Ming Zeng Zhi Zeng Feng-Shou Zhang Lei Zhang Zhen-hua Zhang Zhen-Yu Zhang Kang-Kang Zhao Ming-Gang Zhao Ji-Fang Zhou Zu-Ying Zhou Jing-Jun Zhou Key Laboratory of Particle and Radiation Imaging(Ministry of Education)and Department of Engineering Physics Tsinghua UniversityBeijing 100084 Department of Physics Tsinghua UniversityBeijing 100084 Institute of Physics Academia SinicaTaipei 11529 NUCTECH Company Beijing 100084 YaLong River Hydropower Development Company Chengdu 610051 College of Nuclear Science and Technology Beijing Normal UniversityBeijing 100875 College of Physics Sichuan UniversityChengdu 610065 School of Physics Peking UniversityBeijing 100871 Department of Nuclear Physics China Institute of Atomic EnergyBeijing 102413 Sino-French Institute of Nuclear and Technology Sun Yat-sen UniversityZhuhai 519082 School of Physics Nankai UniversityTianjin 300071 Department of Physics Banaras Hindu UniversityVaranasi 221005 Department of Physics Beijing Normal UniversityBeijing 100875

We operated a p-type point contact high purity germanium(PPCGe)detector(CDEX-1B,1.008 kg)in the China Jinping Underground Laboratory(CJPL)for 500.3 days to search for neutrinoless double beta(0νββ)decay of^(76)Ge.A total of 504.3 kg⋅day effective exposure data was *** anti-coincidence and the multi/single-site event(MSE/SSE)discrimination methods were used to suppress the background in the energy region of interest(ROI,1989–2089 keV for this work)with a factor of 23.A background level of 0.33 counts/(keV⋅kg⋅yr)was *** lower limit on the half life of^(76)Ge 0νββdecay was constrained as T_(1/2)^(0ν)>1.0×10^(23)yr(90%C.L.),corresponding to the upper limits on the effective Majorana neutrino mass:<3.2–7.5 eV.

关键词： neutrinoless double beta decay CDEX point-contact germanium detector ^(76)Ge

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

CEPC Technical Design Report

引用

Radiation Detection Technology and Methods 2024年第1期8卷 I0003-I0016,1-1091页

作者： Waleed Abdallah Tiago Carlos Adorno de Freitas Konstantin Afanaciev Shakeel Ahmad Ijaz Ahmed xiaocong Ai Abid Aleem Wolfgang Altmannshofer Fabio Alves Weiming An Rui An Daniele Paolo Anderle Stefan Antusch Yasuo Arai Andrej Arbuzov Abdesslam Arhrib Mustafa Ashry Sha Bai Yu Bai yang Bai Vipul Bairathi Csaba Balazs Philip Bambade yong Ban Tripamo Bandyopadhyay Shou-shan Bao Desmond P.Barber Ayse Bat Varvara Batozskaya Subash Chandra Behera Alexander Belyaev Michele Bertucci xiao-Jun Bi Yuanjie Bi Tianjian Bian Fabrizio Bianchi Thomas Biekotter Michela Biglietti Shalva Bilanishvili Deng binglin Denis Bodrov Anton Bogomyagkov Serge Bondarenko Stewart Boogert Maarten Boonekamp Marcello Borri Angelo Bosotti Vincent Boudry Mohammed Boukidi Igor Boyko Ivanka Bozovic Giuseppe Bozzi Jean-Claude Brient Anastasiia Budzinskaya Masroor Bukhari Vladimir Bytev Giacomo Cacciapaglia hua Cai Wenyong Cai Wujun Cai Yijian Cai Yizhou Cai Yuchen Cai Haiying Cai huacheng Cai Lorenzo Calibbi Junsong Cang Guofu Cao Jianshe Cao Antoine Chance Xuejun Chang Yue Chang Zhe Chang Xinyuan Chang Wei Chao Auttakit Chatrabhuti Yimin Che Yuzhi Che bin Chen Danping Chen Fuqing Chen Fusan Chen Gang Chen Guoming Chen hua-Xing Chen huirun Chen Jinhui Chen Ji-Yuan Chen Kai Chen Mali Chen Mingjun Chen Mingshui Chen Ning Chen shanhong Chen shanzhen Chen Shao-Long Chen Shaomin Chen shiqiang Chen Tianlu Chen Wei Chen Xiang Chen xiaoyu Chen Xin Chen Xun Chen Xurong Chen Ye Chen Ying Chen Yukai Chen Zelin Chen Zilin Chen Gang Chen Boping Chen Chunhui Chen Hok Chuen Cheng huajie Cheng shan Cheng Tongguang Cheng Yunlong Chi Pietro Chimenti Wen Han Chiu Guk Cho Ming-Chung Chu xiaotong Chu Ziliang Chu Guglielmo Coloretti Andreas Crivellin Hanhua Cui xiaohao Cui Zhaoyuan Cui Brunella D'Anzi ling-Yun Dai Xinchen Dai Xuwen Dai Antonio De Maria Nicola De Filippis Christophe De La Taille Francesca De Mori Chiara De Sio Elisa Del Core Shuangxue Deng Wei-Tian Deng Zhi Deng Ziyan Deng Bhupal Dev Tang Dewen Biagio Di Micco Ran Ding Siqin Dingl Yadong Ding Haiyi Dong Jianin AGH University of Science and Technology Faculty of Physics and Applied Computer ScienceKrakow Anhui University HefeiAnhui Applied Physics Department Federal Urdu University of ArtsScience and TechnologyIslamabad Banaras Hindu University Institute of ScienceVaranasi Bandirma Onyedi Eylul University Bandirma Beihang University Beijing Beijing Computational Science Research Center Beijing Beijing Conveyi LTD Beijing Beijing Glass Research Institute Co. LtdBeijing Beijing Institute of Technology Beijing Beijing Normal University Beijing Brown University ProvidenceRI Budker Institute of Nuclear Physics Novosibirsk Cadi Ayyad University Laboratory of Fundamental and Applied PhysicsPolydisciplinary FacultyMarrakech Cairo University Giza Center for Theory and Computation National Tsing Hua UniversityHsinchu Central China Normal University WuhanHubei Central South University ChangshaHunan Centro de Fisica Teorica de Particulas Universidade Tecnica de LisboaLisboa Chengdu KaitengSifang Digital Radio&TV Equipment Co. LtdChengduSichuan China academy of engineering physics MianyangSichuan China building materials academy Beijing China Center of Advanced Science and Technology Beijing China Institute of Atomic Energy Beijing China Jiliang University HangzhouZhejiang China Nuclear Instrument CO. LTDBeijing China University of Geosciences Beijing China University of Geosciences WuhanHubei China University of Mining and Technology XuzhouJiangsu China West Normal University NanchongSichuan Chongqing University Department of PhysicsChongqing Chulalongkorn University Bangkok City University of Hong Kong Department of PhysicsHong Kong Cockcroft Institute Daresbury Cornell University IthacaNY CPPM(AMU/IPhu&CNRS/INP) Marseille Dalian Minzu University DalianLiaoning Dalian University of Technology Department of PhysicsDalian Deutsches Elektronen-Synchrotron DESY Hamburg Dzhelepov Laboratory of Nuclear Problems of Joint Institute for Nuclear Research(DLNP JINR) Dubna East China University Of Science And Technol

The Circular Electron Positron Collider(CEPC)is a large scientific project initiated and hosted by China,fostered through extensive collaboration with international *** complex comprises four accelerators:a 30 GeV linac,a 1.1 GeV Damping Ring,a Booster capable of achieving energies up to 180 GeV,and a Collider operating at varying energy modes(Z,W,H,and tt).The linac and Damping Ring are situated on the surface,while the subterranean Booster and Collider are housed in a 100 km circumference underground tunnel,strategically accommodating future expansion with provisions for a potential Super Proton Proton Collider(SPPC).The CEPC primarily serves as a Higgs *** its baseline design with synchrotron radiation(SR)power of 30 MW per beam,it can achieve a luminosity of 5×10^(34)cm^(-2)s^(-1)per interaction point(IP),resulting in an integrated luminosity of 13 ab^(-1)for two IPs over a decade,producing 2.6 million Higgs *** the SR power to 50 MW per beam expands the CEPC's capability to generate 4.3 million Higgs bosons,facilitating precise measurements of Higgs coupling at sub-percent levels,exceeding the precision expected from the HL-LHC by an order of *** Technical Design Report(TDR)follows the Preliminary Conceptual Design Report(Pre-CDR,2015)and the Conceptual Design Report(CDR,2018),comprehensively detailing the machine's layout,performance metrics,physical design and analysis,technical systems design,R&D and prototyping efforts,and associated civil engineering ***,it includes a cost estimate and a preliminary construction timeline,establishing a framework for forthcoming engineering design phase and site selection *** is anticipated to begin around 2027-2028,pending government approval,with an estimated duration of 8 *** commencement of experiments and data collection could potentially be initiated in the mid-2030s.

关键词： initiated exceeding precise

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Efficacy and safety of Shenyankangfu Tablet,a Chinese patent medicine,for primary glomerulonephritis:A multicenter randomized controlled trial

引用

Journal of Integrative Medicine 2021年第2期19卷 111-119页

作者： Jie Wu Shu-wei Duan Hong-tao yang Yue-yi Deng Wei li Ya-ni He Zhao-hui Ni yong-li Zhan shan lin Zhi-yong Guo Jun Zhu Jing-ai Fang Xu-sheng liu li-hua Wang Rong Wang Nian-song Wang xiao-hong Cheng li-qun He Ping Luo shi-ren Sun Ji-feng Sun Ai-ping Yin Geng-ru jiang Hong-yu Chen Wen-hu liu Hong-li lin Meng liang Lu Ma Ming Chen li-qun Song Jian Chen Qing Zhu Chang-ying Xing Yun li Ji-ning Gao Rong-shan li Ying li Hao Zhang Ying Lu Qiao-ling Zhou Jun-zhou Fu Qiang He Guang-yan Cai Xiang-mei Chen Department of Nephrology Chinese People’s Liberation Army General HospitalChinese People’s Liberation Army Institute of NephrologyState Key Laboratory of Kidney Diseases(2011DAV00088)National Clinical Research Center for Kidney DiseasesBeijing 100853China Department of Nephrology First Teaching Hospital of Tianjin University of Traditional Chinese MedicineTianjin 300192China Department of Nephrology Longhua HospitalShanghai University of Traditional Chinese MedicineShanghai 200032China Department of Nephrology Shandong University of Traditional Chinese Medicine Affiliated HospitalJinan 250011.Shandong ProvinceChina Department of Nephrology Daping HospitalArmy Medical UniversityChongqing 400042China Department of Nephrology Renji HospitalShanghai Jiao Tong UniversityShanghai 200127China Department of Nephrology Guang’anmen HospitalChina Academy of Traditional Chinese Medical SciencesBeijing 100053China Department of Nephrology Tianjin Medical University General HospitalTianjin 300052China Department of Nephrology Changhai Hospital of ShanghaiNaval Medical UniversityShanghai 200433China Department of Nephrology West China HospitalChengdu 610083Sichuan ProvinceChina Department of Nephrology First Affiliated Hospital of Shanxi Medical UniversityTaiyuan 030001Shanxi ProvinceChina Department of Nephrology Guangdong Provincial Hospital of Chinese MedicineGuangzhou 510120Guangdong ProvinceChina Department of Nephrology Shanxi Medical University Second Affiliated HospitalTaiyuan 030001Shanxi ProvinceChina Department of Nephrology Shandong Provincial HospitalJinan 250021Shandong ProvinceChina Department of Nephrology and Rheumatology Affiliated Sixth People’s HospitalShanghai Jiao Tong UniversityShanghai 200233China Department of Nephrology Shaanxi Traditional Chinese Medicine HospitalXi'an 710003Shaanxi ProvinceChina Department of Nephrology Shuguang HospitalShanghai University of Traditional Chinese MedicineShanghai 200021China Department of Nephrology Jilin University Se

Background:Shenyankangfu Tablet(SYKFT)is a Chinese patent medicine that has been used widely to decrease proteinuria and the progression of chronic kidney ***:This trial compared the efficacy and safety of SYKFT,for the control of proteinuria in primary glomerulonephritis patients,against the standard drug,losartan ***,setting,participants and intervention:This was a multicenter,double-blind,randomized,controlled clinical *** glomerulonephritis patients,aged 18-70 years,with blood pressure≤140/90 mmHg,estimated glomerular filtration rate(eGFR)>45 mL/min per 1.73 ㎡,and 24-hour proteinuria level of 0.5-3.0 g,were recruited in 41 hospitals across 19 provinces in China and were randomly divided into five groups:SYKFT,losartan potassium 50 mg or 100 mg,SYKFT plus losartan potassium 50 mg or 100 *** outcome measu res:The primary outcome was change in the 24-hour proteinuria level,after 48 weeks of ***:A total of 735 participants were *** percent decline of urine protein quantification in the SYKFT group after 48 weeks was 8.78%±2.56%(P=0.006)more than that in the losartan 50 mg group,which was 0.51%±2.54%(P=1.000)less than that in the losartan 100 mg *** with the losartan potassium 50 mg group,the SYKFT plus losartan potassium 50 mg group had a 13.39%±2.49%(Pline did not change statistically *** average change in TCM syndrome score between the patients who took SYKFT(-3.00[-6.00,-2.00])and who did not take SYKFT(-2.00[-5.00,0])was statistically significant(P=0.003).No obvious adverse reactions were observed in any ***:SYKFT decreased the proteinur

关键词： Herbal medicine,Chinese Shenyankangfu Tablet Primary glomerulonephritis Randomized controlled trial Double blind Double dummy

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma:A single-arm, multicenter, prospective study

引用

Hepatobiliary & Pancreatic Diseases International 2022年第2期21卷 106-112页

作者： ren-Yi Su Sun-bin ling Qiao-Nan shan Xu-yong Wei Rui Wang Chang-Ku Jia li Zhuang Tian Shen li-Min Ding Zhi-Dan Xu Lai-Bang Luo li-Bo Sun Guang-Ming li Tai-shi Fang Nan jiang Kun Zhang Zhao-Jie Su Zhi-Hai Peng ren Lang Tao jiang Qiang He lin-Sen Ye yang yang Yu-Ting He Wen-Zhi Guo liu-Gen Lan Xu-yong Sun Dong Chen Zhi-Shui Chen Da-Wei Zhou Shao-Jun Ye Qi-Fa Ye Min Tian Jian-hua shi Bo Wang jiang liu Qian Lu Wei Rao Jin-Zhen Cai Tao Lv Jia-Yin yang Pu-Sen Wang lin Zhong Jing-Sheng Ma Qi-Gen li Sheng-Dong Wu Chang-jiang Lu Cai-De Lu Dong-hua Zhang Xuan Wang Zi-Qiang li Mu-Jian Teng Jun-Jie li Wen-Tao jiang Jian-hua li Quan-Bao Zhang Ning-Qi Zhu Zheng-Xin Wang Kang He Qiang Xia Shao-hua Song Zhi-ren Fu Wei Qiu Guo-Yue Lv Rui-Peng Song Ji-Zhou Wang Zheng Wang Jian Zhou Gang Chen Ying-Peng Zhao li li Ze-Min hu Qi-Jie Luo Zhong-Zhou Si bin Xie xiao-Shun He Zhi-yong Guo Shu-Sen Zheng xiao Xu Department of Hepatobiliary and Pancreatic Surgery The Center for Integrated Oncology and Precision MedicineAffiliated Hangzhou First People’s HospitalZhejiang University School of MedicineHangzhou 310006China NHC Key Laboratory of Combined Multi-organ Transplantation Hangzhou 310003China Department of Hepatobiliary and Pancreatic Surgery Shulan(Hangzhou)HospitalZhejiang Shuren University School of MedicineHangzhou 310022China Department of Hepatobiliary and Pancreatic Surgery The First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China Department of Transplantation Jiangxi Provincial People’s Hospital Affiliated to Nanchang UniversityNanchang 330006China liver Transplantation Center Beijing You’an HospitalCapital Medical UniversityBeijing 100069China Department of Hepatic Surgery National Clinical Research Center for Infectious DiseaseShenzhen Third People’s HospitalThe Second Affiliated Hospital of Southern University of Science and TechnologyShenzhen 518112China Department of General Surgery Xiang’an Hospital of Xiamen UniversityXiamen 361000China Deartment of Hepatobiliary and Pancreaticosplenic Surgery Beijing Chaoyang HospitalCapital Medical UniversityBeijing 100020China Department of Hepatic Surgery and liver Transplantation Center The Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510630China Department of Hepatobiliary and Pancreatic Surgery The First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052China Department of liver Transplantation The Second Affiliated Hospital of Guangxi Medical UniversityNanning 530000China Institute of Organ Transplantation Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China Institute of Hepatobiliary Diseases of Wuhan University Transplant Center of Wuhan UniversityHubei Key Laboratory of Medical Technology on TransplantationZhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Hepatobiliary Surgery The First Affiliated Hos

Mammalian target of rapamycin(m TOR) inhibitor as an attractive drug target with promising antitumor effects has been widely investigated. High quality clinical trial has been conducted in liver transplant(LT) recipients in Western countries. However, the pertinent studies in Eastern world are paucity. Therefore, we designed a clinical trial to test whether sirolimus can improve recurrence-free survival(RFS) in hepatocellular carcinoma(HCC) patients beyond the Milan criteria after LT. This is an open-labeled, single-arm, prospective, multicenter, and real-world study aiming to evaluate the clinical outcomes of early switch to sirolimus-based regimens in HCC patients after LT. Patients with a histologically proven HCC and beyond the Milan criteria will be enrolled. The initial immunosuppressant regimens are center-specifc for the frst 4-6 weeks. The following regimens integrated sirolimus into the regimens as a combination therapy with reduced calcineurin inhibitors based on the condition of patients and centers. The study is planned for 4 years in total with a 2-year enrollment period and a 2-year follow-up. We predict that sirolimus conversion regimen will provide survival benefts for patients particular in the key indicator RFS as well as better quality of life. If the trial is conducted successfully, we will have a continued monitoring over a longer follow-up time to estimate indicator of overall survival. We hope that the outcome will provide better evidence for clinical decision-making and revising treatment guidelines based on Chinese population data.

关键词： Sirolimus Immunosuppressive agents Hepatocellular carcinoma liver transplantation Conversion

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Association of Overlapped and Un-overlapped Comorbidities with COVID-19 Severity and Treatment Outcomes: A Retrospective Cohort Study from Nine Provinces in China

引用

Biomedical and Environmental Sciences 2020年第12期33卷 893-905页

作者： MA Yan Zhu Dong shan CHEN ren Bo shi Nan Nan liU Si Hong FAN Yi Pin WU Gui hui yang Pu Ye BAI jiang Feng CHEN Hong CHEN li Ying FENG Qiao GUO Tuan Mao HOU yong hu Gui Fen hu xiao Mei hu Yun Hong huANG Jin huANG Qiu hua huANG Shao Zhen JI liang JIN Hai Hao LEI xiao li Chun Yan li Min Qing li Qun Tang li Xian yong liU Hong De liU Jin Ping liU Zhang MA Yu Ting MAO Ya MO liu Fen NA hui WANG Jing Wei SONG Fang li SUN Sheng WANG Dong Ting WANG Ming Xuan WANG xiao Yan WANG Yin Zhen WANG Yu Dong WU Wei WU Lan Ping xiao Yan hua XIE Hai Jun XU Hong Ming XU Shou Fang XUE Rui Xia yang Chun yang Kai Jun YUAN Sheng li ZHANG Gong Qi ZHANG Jin Bo ZHANG lin Song ZHAO Shu Sen ZHAO Wan Ying ZHENG Kai ZHOU Ying Chun Zhu Jun Teng Zhu Tian Qing ZHANG hua Min WANG Yan Ping WANG yong Yan 无 Institute of Basic Research in Clinical Medicine China Academy of Chinese Medical SciencesBeijing 100700China Centre for Health Management and Policy Research School of Public HealthCheeloo College of MedicineShandong UniversityJinan 250012ShandongChina Institute of Information on Traditional Chinese Medicine China Academy of Chinese Medical SciencesBeijing 100700China Department of Tuberculosis The Public Health Clinical Center of ChengduChengdu 610066SichuanChina Department of Infectious Disease Shaanxi Infectious Disease HospitalXi'an 610113ShaanxiChina Department of Infectious Disease Yulin Chinese Medicine HospitalYulin 719000ShaanxiChina President's Office The First Hospital of QiqiharQiqihar 161005HeilongjiangChina Department of Traditional Chinese Medicine Shangluo Central HospitalShangluo 726000ShaanxiChina Department of Traditional Chinese Medicine The People's Hospital of QitaiheQitaihe 154603HeilongjiangChina Department of Scientific Research Xianyang Central HospitalXianyang 712000ShaanxiChina Department of traditional Chinese medicine The First Affiliated Hospital of Anhui University of Traditional Chinese MedicineHefei 230012AnhuiChina Department of Infectious Disease Heping Hospital Affiliated to Changzhi Medical CollegeChangzhi 046000ShanxiChina Department of Traditional Chinese Medicine Langfang Hospital of Chinese MedicineLangfang 065000HeibeiChina Department of Traditional Chinese Medicine Xingtai Hospital of Chinese MedicineXingtai 054001HeibeiChina Department of Traditional Chinese Medicine The People's Hospital of Guangxi Zhuang Autonomous RegionNanning 168600GuangxiChina Department of Traditional Chinese Medicine The First People'sHospital of FangchenggangFangchenggang 538001GuangxiChina Department of Traditional Chinese Medicine Mianyang Hospital of Traditional Chinese MedicineMianyang 621000SichuanChina Department of Traditional Chinese Medicine Liuzhou People's HospitalLiuzhou 545006GansuChina Department of Traditional Chinese Medici

Objective Several COVID-19 patients have overlapping comorbidities. The independent role of each component contributing to the risk of COVID-19 is unknown, and how some non-cardiometabolic comorbidities affect the risk of COVID-19 remains *** A retrospective follow-up design was adopted. A total of 1,160 laboratory-confirmed patients were enrolled from nine provinces in China. Data on comorbidities were obtained from the patients’ medical records. Multivariable logistic regression models were used to estimate the odds ratio(OR) and 95% confidence interval(95% CI) of the associations between comorbidities(cardiometabolic or non-cardiometabolic diseases), clinical severity, and treatment outcomes of *** Overall, 158(13.6%) patients were diagnosed with severe illness and 32(2.7%) had unfavorable outcomes. Hypertension(2.87, 1.30–6.32), type 2 diabetes(T2 DM)(3.57, 2.32–5.49),cardiovascular disease(CVD)(3.78, 1.81–7.89), fatty liver disease(7.53, 1.96–28.96), hyperlipidemia(2.15, 1.26–3.67), other lung diseases(6.00, 3.01–11.96), and electrolyte imbalance(10.40, 3.00–26.10)were independently linked to increased odds of being severely ill. T2 DM(6.07, 2.89–12.75), CVD(8.47,6.03–11.89), and electrolyte imbalance(19.44, 11.47–32.96) were also strong predictors of unfavorable outcomes. Women with comorbidities were more likely to have severe disease on admission(5.46,3.25–9.19), while men with comorbidities were more likely to have unfavorable treatment outcomes(6.58, 1.46–29.64) within two *** Besides hypertension, diabetes, and CVD, fatty liver disease, hyperlipidemia, other lung diseases, and electrolyte imbalance were independent risk factors for COVID-19 severity and poor treatment outcome. Women with comorbidities were more likely to have severe disease, while men with comorbidities were more likely to have unfavorable treatment outcomes.

关键词： Comorbidities COVID-19 Severity Gender Age Treatment outcome

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma(CHANCE001)

引用

Signal Transduction and Targeted Therapy 2023年第3期8卷 1198-1207页

作者： Hai-Dong Zhu Hai-liang li Ming-Sheng huang Wei-Zhu yang Guo-Wen Yin bin-Yan Zhong Jun-hui Sun Zhi-Cheng Jin Jian-Jian Chen Nai-Jian Ge Wen-bin Ding Wen-hui li Jin-hua huang Wei Mu shan-Zhi Gu Jia-Ping li hui Zhao Shu-Wei Wen Yan-Ming Lei Yu-Sheng Song Chun-Wang Yuan Wei-Dong Wang Ming huang Wei Zhao Jian-bing Wu Song Wang Xu Zhu Jian-Jun Han Wei-Xin ren Zai-Ming Lu Wen-Ge Xing yong Fan Hai-Lan lin Zi-Shu Zhang Guo-hui Xu Wen-Hao hu Qiang Tu Hong-Ying Su Chuan-Sheng Zheng yong Chen Xu-Ya Zhao Zhu-Ting Fang Qi Wang Jin-Wei Zhao Ai-bing Xu Jian Xu Qing-hua Wu huan-Zhang Niu Jian Wang Feng Dai Dui-Ping Feng Qing-Dong li Rong-Shu shi Jia-Rui li Guang yang Hai-bin shi Jian-Song Ji Yu-E liu Zheng Cai Po yang yang Zhao xiao-li Zhu li-Gong Lu Gao-Jun Teng Center of Interventional Radiology&Vascular Surgery Department of RadiologyZhongda HospitalMedical SchoolSoutheast UniversityNanjing 210009China Department of Minimally invasive Intervention The Affiliated Cancer Hospital of Zhengzhou UniversityZhengzhou 450008China Department of Interventional Radiology the Third Affiliated HospitalSun Yat-Sen UniversityGuangzhou 510630China Department of Interventional Radiology Union Hospital of Fujian Medical UniversityFuzhou 350001China Department of Interventional Radiology Jiangsu Cancer Hospital&Jiangsu Institute of Cancer Research&The Affiliated Cancer Hospital of Nanjing Medical UniversityNanjing 210009China Department of Interventional Radiology The First Affiliated Hospital of Soochow UniversitySoochow UniversitySuzhou 215006China Hepatobiliary and Pancreatic Interventional Treatment Center Division of Hepatobiliary and Pancreatic SurgeryThe First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China Department of Interventional Radiology Eastern Hospital of Hepatobiliary SurgeryNavy Medical University(Second Military Medical University)Shanghai 200438China Department of Interventional Radiology Nantong First People’s HospitalNantong 226001China Department of Interventional Radiology Yancheng Third People’s HospitalYancheng 224008China Department of Minimally Invasive Interventional Therapy Sun YatSen University Cancer CenterGuangzhou 510060China Department of Vascular Surgery Southwest HospitalThird Military Medical University(Army Medical University)Chongqing 400038China. Department of Interventional Radiology Hunan Cancer HospitalChangsha 410031China Department of Interventional Oncology The First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510080China Department of Interventional Radiology The Hospital of Nantong UniversityNantong 226001China Department of Interventional Therapy Shanxi Tumor HospitalTaiyuan 030001China Department of Interventional Radiology Tibet Autonomous Region People’s

There is considerable potential for integrating transarterial chemoembolization(TACE),programmed death-(ligand)1(PD-[L]1)inhibitors,and molecular targeted treatments(MTT)in hepatocellular carcinoma(HCC).It is necessary to investigate the therapeutic efficacy and safety of TACE combined with PD-(L)1 inhibitors and MTT in real-world *** this nationwide,retrospective,cohort study,826 HCC patients receiving either TACE plus PD-(L)1 blockades and MTT(combination group,n=376)or TACE monotherapy(monotherapy group,n=450)were included from January 2018 to May *** primary endpoint was progression-free survival(PFS)according to modified *** secondary outcomes included overall survival(OS),objective response rate(ORR),and *** performed propensity score matching approaches to reduce bias between two *** matching,228 pairs were included with a predominantly advanced disease *** PFS in combination group was 9.5 months(95%confidence interval[CI],8.4-11.0)versus 8.0 months(95%CI,6.6-9.5)(adjusted hazard ratio[HR],0.70,P=0.002).OS and ORR were also significantly higher in combination group(median OS,19.2[16.1-27.3]vs.15.7 months[13.0-20.2];adjusted HR,0.63,P=0.001;ORR,60.1%vs.32.0%;Pbination and monotherapy groups,*** results suggest that TACE plus PD-(L)1 blockades and MTT could significantly improve PFS,OS,and ORR versus TACE monotherapy for Chinese patients with predominantly advanced HCC in real-world practice,with an acceptable safety profile.

关键词： hepatocellular targeted matching

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Expert Consensus on Pathological Diagnosis of Intrahepatic Cholangiocarcinoma(2022 version)

引用

Journal of Clinical and Translational Hepatology 2023年第7期11卷 1553-1564页

作者： Han Wang Jun Chen Xin Zhang Xia Sheng xiao-Yan Chang Jie Chen Min-shan Chen hui Dong Guang-Jie Duan He-Ping hu Zhi-yong huang Wei-Dong Jia xiao-Qing jiang Dong Kuang shan-shan li Zeng-shan li Chang-li Lu Shu-Kui Qin Xue-shan Qiu li-Juan Qu Chun-Kui Shao Feng Shen Guo-Ming shi Su-Sheng shi Yu-Jun shi hui-Chuan Sun xiao-Dong Teng bin Wang Zhan-Bo Wang Tian-Fu Wen Jia-Mei yang Qiao-Qiao yang Sheng-Long Ye Hong-Fang Yin Zhen-Gang Yuan Jing-Ping Yun Feng-lin Zang Hong-Qi Zhang li-Hong Zhang Jing-Min Zhao Jian Zhou Wei-Xun Zhou Jia Fan xiao-Ping Chen Wan Yee Lau Yuan Ji Wen-Ming Cong Chinese Society of liver Cancer of Chinese Anti-Cancer Association Digestive Disease Group of Chinese Society of Pathology,Chinese Medical Association Chinese Society of Pathology of Chinese Anti-Cancer Association Hepatic Surgery Group of Chinese Society of Surgery,Chinese Medical Association Biliary Tract Tumor Committee of China Anti-Cancer Association Chinese Society of Clinical Oncology IDepartment of Pathology Eastern Hepatobilary Surgery HospitalNaval Medical UniversityShanghaiChina Department of Pathology the Affiliated Drum Tower HospitalNanjing University Medical SchoolNanjingJiangsuChina Department of Pathology Zhongshan HospitalFudan UniversityShanghaiChina Department of Pathology Minhang HospitalFudan Uni-versityShanghaiChina Department of Pathology Peking Union Medical College HospitalChinese Academy of Medical Sci-ences and Peking Union Medical CollegeBeijingChina Department of liver Surgery Sun Yat-Sen University Cancer CenterGuangzhouGuangdongChina Department of Pathology The First Affiliated HospitalArmy Medical UniversityChongqingChina Department of Hepatobiliary Medicine Eastern Hepatobiliary Surgery HospitalNaval Medical UniversityShanghaiChina Hepatic Surgery Center Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWu-hanHubeiChina Department of General Surgery The First Affliated Hospital of USTCDivision of Life Science and Medi-cineUniversity of Science and Technology of ChinaHefeiAnhuiChina Department of Biliary Surgery I Eastern Hepatobil-iary Surgery HospitalNaval Medical UniversityShanghaiChina Department of Pathology Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanHubeiChina Department of Pathology The First Afiliated Hospital of Zhengzhou UniversityZhengzhou UniversityZhengzhouHenanChina Department of Pathology Xijing Hospi-talAir Force Medical UniversityXi'anShaanxiChina Department of Pathology West China HospitalSichuan UniversityChengduSichuanChina Cancer Center of Jinling Hospital Nanjing University of Chinese MedicineNanjingJiangsuChina Department of Pathology The First Affiliated HospitalChina Medical UniversityShenyangLiaoningChina Department of Pathology The 900 Hospital of the Chinese People's Liberation Army Joint Logistics TeamFuzhouFujianChina Department of Pathology The Third Affiliated HospitalSun Yat-Sen UniversityGuangz

Intrahepatic cholangiocarcinoma(iCCA)can originate from the large bile duct group(segment bile ducts and area bile ducts),small bile duct group(septal bile ducts and interlobular bile ducts),and terminal bile duct group(bile ductules and canals of Hering)of the intrahepatic biliary tree,which can be histopathological corresponding to large duct type iCCA,small duct type iCCA and iCCA with ductal plate malformation pattern,and cholangiolocarcinoma,*** challenge in pathological diagnosis of above subtypes of iCCA falls in the distinction of cellular morphologies,tissue structures,growth patterns,invasive behaviors,immunophenotypes,molecular mutations,and surgical *** these reasons,this expert consensus provides nine recommendations as a reference for standardizing and refining the diagnosis of pathological subtypes of iCCA,mainly based on the 5th edition of the World Health Organization Classification of Tumours of the Digestive System.

关键词： Intrahepatic cholangiocarcinoma Pathology Histological type Immunohistochemistry Molecular variation

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Prevalence, awareness, treatment, and control of hypertension in the non-dialysis chronic kidney disease patients

引用

Chinese Medical Journal 2013年第12期126卷 2276-2280页

作者： ZHENG Ying CAI Guang-yan CHEN Xiang-mei FU Ping CHEN jiang-hua DING xiao-qiang YU Xue-qing lin Hong-li liU Jian XIE Ru-juan WANG li-ning NI Zhao-hui liU Fu-you YIN Ai-ping XING Chang-ying WANG li shi Wei liU Jian-she HE Ya-ni DING Guo-hua li Wen-ge WU Guang-li MIAO li-ning CHEN Nan SU Zhen MEI Chang-lin ZHAO Jiu-yang GU yong BAI Yun-kai LUO hui-min lin shan CHEN Meng-hua GONG li yang Yi-bin yang xiao-ping li Ying WAN Jian-xin WANG Nian-song li Hai-ying XI Chun-sheng HAO li XU Yan FANG Jing-ai liU Bi-cheng li Rong-shan WANG Rong ZHANG Jing-hong WANG Jian-qin LOU Tan-qi SHAO Feng-min MEI Feng liU Zhi-hong YUAN Wei-jie SUN shi-ren ZHANG ling ZHOU Chun-hua CHEN Qin-kai JIA Shun-lian GONG Zhi-feng GUAN Guang-ju XIA Tian ZHONG liang-bao Department of Nephrology State key Laboratory of Kidney Disease Chinese PLA General Hospital Beijing 100853 China Nephrology Institute of the Chinese People's liberation Army Chinese People's Liberation Army Key Laboratory of Nephrology Beijing 100853 China Department of Nephrology West China Hospital of Sichuan University Chengdu Sichuan 610041 China Department of Nephrology First Affiliated Hospital School of Medicine Zhejiang University Hangzhou Zhejiang 310003 China Department of Nephrology Zhongshan Hospital Fudan University Shanghai 200032 China Department of Nephrology First Affiiated Hospital of Sun Yat-sen University Guangzhou Guangdong 510080 China Department of Nephrology First Affiliated Hospital of Dalian Medical University Dalian Liaoning 116011 China Department of Nephrology First Affiliated Hospital of Xinjiang Medical University Urumqi Xinjiang 830054 China Department of Nephrology First Affiliated Hospital of Harbin Medical University Harbin Heilongjiang 150001 China Department of Nephrology First Afftiated Hospital of China Medical University Shenyang Liaoning 110001 China Department of Nephrology Renji Hospital School of Medicine Shanghai Jiao Tong University Shanghai 200025 China Department of Nephrology Second Xiangya Hospital Central South University Changsha Hunan 410000 China Department of Nephrology First Affiliated Hospital of Medical College Xi'an Jiaotong University Xi'an Shaanxi 710061 China Department of Nephrology First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital) Nanjing Jiangsu 210029 China Department of Nephrology Sichuan Provincial People's Hospital Chengdu Sichuan 610072 China Department of Nephrology Guangdong Provincial People's Hospital Guangzhou Guangdong 510030 China Department of Nephrology Affliated Xiehe Hospital Tongji Medical College Huazhong Science and Technology University Wuhan Hubei 430022 China Department of Nephrology Daping Hospital Third Military Medi

Background Data on the epidemiology of hypertension in Chinese non-dialysis chronic kidney disease （CKD） patients are *** aim of the present study was to investigate the prevalence,awareness,treatment,and control of hypertension in the non-dialysis CKD patients through a nationwide,multicenter study in *** The survey was performed in 61 tertiary hospitals in 31 provinces,municipalities,and autonomous regions in China （except Hong Kong,Macao,and Taiwan）.Trained physicians collected demographic and clinical data and measured blood pressure （BP） using a standardized *** was defned as systolic BP ≥140 mmHg and/or diastolic BP ≥90 mmHg,and/or use of antihypertensive *** 〈140/90 mmHg and 〈130/80 mmHg were used as the 2 thresholds of hypertension *** multivariate logistic regression with adjustment for sex and age,we analyzed the association between CKD stages and uncontrolled hypertension in non-dialysis CKD *** The analysis included 8927 non-dialysis CKD *** prevalence,awareness,and treatment of hypertension in non-dialysis CKD patients were 67.3%,85.8%,and 81.0%,*** hypertensive CKD patients,33.1% and 14.1% had controlled BP to 〈140/90 mmHg and 〈130/80 mmHg,*** successive CKD stages,the prevalence of hypertension in non-dialysis CKD patients increased,but the control of hypertension decreased （P〈0.001）.When the threshold of BP 〈130/80 mmHg was considered,the risk of uncontrolled hypertension in CKD 2,3a,3b,4,and 5 stages increased 1.3,1.4,1.4,2.5,and 4.0 times compared with CKD 1 stage,respectively （P〈0.05）.Using the threshold of 〈140/90 mmHg,the risk of uncontrolled hypertension increased in advanced stages （P〈0.05）.Conclusions The prevalence of hypertension Chinese non-dialysis CKD patients was high,and the hypertension control was *** successive CKD stages,the risk of uncontrolled hypertension increased.

关键词： non-dialysis chronic kidney disease chronic kidney disease stages hypertension epidemiology

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

2022年CHINET三级医院细菌耐药监测

引用

中国感染与化疗杂志 2024年第3期24卷 277-286页

作者：郭燕胡付品朱德妹汪复蒋晓飞徐英春张小江张峰波季萍谢轶肖玉玲王传清付盼徐元宏黄颖孙自镛陈中举孙景勇陈庆褚云卓田素飞胡志东李金俞云松林洁单斌许云敏郭素芳王艳艳魏莲花李可可张泓潘芬胡云建艾效曼卓超苏丹虹郭大文赵金英喻华黄湘宁刘文恩李艳明金炎邵春红徐雪松李威王山梅楚亚菲张利侠马娟周树平周艳朱镭孟晋华董方吕志勇胡芳芳沈瀚周万青贾伟李刚吴劲松卢月梅李继红孙倩段金菊康建邦马晓波郑燕青郭如意朱焱陈运生孟青王世富胡雪飞黄文辉李娟石泉贵杨娟热孜瓦古丽·阿不力米提黄莉莉邵雪君任晓艳李冬张群陈雪黎日海徐洁丽高凯杰徐璐林琳张卓刘健龙付敏郭映辉张文超王增国贾凯夏云孙珊杨慧敏苗艳周明明张诗海刘红娟陈楠李婵沈继录门万琪王鹏张晓威刘彦彦安勇复旦大学附属华山医院抗生素研究所国家卫健委抗生素临床药理重点实验室上海200040 北京协和医院新疆医科大学第一附属医院四川大学华西医院复旦大学附属儿科医院安徽医科大学第一附属医院华中科技大学同济医学院附属同济医院上海交通大学医学院附属瑞金医院中国医科大学附属第一医院天津医科大学总医院浙江大学医学院附属邵逸夫医院昆明医科大学第一附属医院内蒙古医科大学附属医院甘肃省人民医院上海交通大学医学院附属儿童医院北京医院广州医科大学附属第一医院哈尔滨医科大学附属第一医院四川省人民医院中南大学湘雅医院山东省立医院吉林大学中日联谊医院河南省人民医院陕西省人民医院江西省儿童医院山西省儿童医院首都医科大学附属北京儿童医院贵州省人民医院南京大学医学院附属鼓楼医院宁夏医科大学总医院深圳市人民医院河北医科大学第二医院山西医科大学第二医院厦门大学附属第一医院福建省泉州市第一医院深圳市儿童医院山东大学齐鲁儿童医院南昌大学第一附属医院青海大学附属医院西藏军区总医院乌鲁木齐市第一人民医院(乌鲁木齐儿童医院) 苏州大学附属儿童医院云南省腾冲市人民医院重庆医科大学附属儿童医院广西桂平市人民医院河南省儿童医院沈阳市儿童医院湖南省儿童医院河北省儿童医院西安市儿童医院重庆医科大学附属第一医院陕西省神木市医院浙江省儿童医院安徽省儿童医院天津市儿童医院安徽医科大学第四附属医院长春市儿童医院邢台市第九医院复旦大学附属华山医院检验科国家卫健委抗生素临床药理重点实验室上海200040

目的监测2022年CHINET三级医院临床分离菌对抗菌药物的敏感性。方法国内58所三级医院临床分离菌采用纸片扩散法或商品化药敏试验自动测试仪按CHINET统一监测技术方案进行抗菌药物敏感性试验。结果按CLSI M1002022年版折点标准判断。结... 详细信息

目的监测2022年CHINET三级医院临床分离菌对抗菌药物的敏感性。方法国内58所三级医院临床分离菌采用纸片扩散法或商品化药敏试验自动测试仪按CHINET统一监测技术方案进行抗菌药物敏感性试验。结果按CLSI M1002022年版折点标准判断。结果收集2022年1月1日-12月31日上述医院临床分离菌共318013株,其中革兰阳性菌占29.5%,革兰阴性菌占70.5%。金黄色葡萄球菌、表皮葡萄球菌和其他凝固酶阴性葡萄球菌(除假中间葡萄球菌和施氏葡萄球菌外)中甲氧西林耐药株的检出率分别为28.3%、76.7%和77.9%。MRSA中有94.0%的菌株对甲氧苄啶-磺胺甲噁唑敏感;MRSE中有90.8%的菌株对利福平敏感,未发现万古霉素耐药株。肠球菌属中粪肠球菌对多数测试抗菌药物的耐药率均显著低于屎肠球菌,两者中均有少数万古霉素耐药株。2022年儿童和成人中分离的非脑膜炎肺炎链球菌中PSSP的检出率分别为94.2%和95.7%。除克雷伯菌属细菌对碳青霉烯类的耐药率范围为21.7%~23.1%外,其他细菌的耐药率多在13.1%以下。除天然耐药菌株外,其他肠杆菌目细菌对替加环素、黏菌素和多黏菌素B高度敏感,耐药率范围为0.1%~13.3%。铜绿假单胞菌对美罗培南的耐药率从2019年的23.5%下降至2022年的18.0%;鲍曼不动杆菌对美罗培南的耐药率亦从2019年的79.0%下降至2022年的72.5%。结论三级医院临床分离菌对常见抗菌药物的耐药率仍呈增长趋势,但碳青霉烯类耐药肺炎克雷伯菌、铜绿假单胞菌、鲍曼不动杆菌等多种重要耐药细菌的检出率近年来呈现连续下降趋势,提示加强细菌耐药监测,开展多学科联动的方式对控制耐药细菌的流行播散是行之有效的。

关键词：三级医院细菌耐药监测药物敏感性试验碳青霉烯类耐药革兰阴性杆菌

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：